229 related articles for article (PubMed ID: 23278570)
21. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
[TBL] [Abstract][Full Text] [Related]
22. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital.
Pittayanon R; Treeprasertsuk S; Phanthumchinda K
J Med Assoc Thai; 2009 Apr; 92(4):478-82. PubMed ID: 19374297
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
Jensen P; Bril V
J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
[TBL] [Abstract][Full Text] [Related]
24. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
[TBL] [Abstract][Full Text] [Related]
25. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
[TBL] [Abstract][Full Text] [Related]
26. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
[TBL] [Abstract][Full Text] [Related]
27. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
Wolfe GI; Barohn RJ; Foster BM; Jackson CE; Kissel JT; Day JW; Thornton CA; Nations SP; Bryan WW; Amato AA; Freimer ML; Parry GJ;
Muscle Nerve; 2002 Oct; 26(4):549-52. PubMed ID: 12362423
[TBL] [Abstract][Full Text] [Related]
28. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of therapeutic options used for myasthenia gravis.
Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
[TBL] [Abstract][Full Text] [Related]
30. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
Ferrero B; Durelli L
Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
[TBL] [Abstract][Full Text] [Related]
31. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
[TBL] [Abstract][Full Text] [Related]
32. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial.
Katzberg HD; Barnett C; Merkies IS; Bril V
Muscle Nerve; 2014 May; 49(5):661-5. PubMed ID: 24810970
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
[TBL] [Abstract][Full Text] [Related]
34. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
Pasnoor M; Wolfe GI; Nations S; Trivedi J; Barohn RJ; Herbelin L; McVey A; Dimachkie M; Kissel J; Walsh R; Amato A; Mozaffar T; Hungs M; Chui L; Goldstein J; Novella S; Burns T; Phillips L; Claussen G; Young A; Bertorini T; Oh S
Muscle Nerve; 2010 Mar; 41(3):370-4. PubMed ID: 19882635
[TBL] [Abstract][Full Text] [Related]
35. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
Heatwole C; Johnson N; Holloway R; Noyes K
J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
[TBL] [Abstract][Full Text] [Related]
37. Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
Barnett C; Bril V; Kapral M; Kulkarni AV; Davis AM
Neurology; 2017 Dec; 89(23):2357-2364. PubMed ID: 29101274
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
[TBL] [Abstract][Full Text] [Related]
39. [Contribution of intravenous immunoglobulins to the treatment of myasthenia].
Gajdos P
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S30-4. PubMed ID: 10896986
[TBL] [Abstract][Full Text] [Related]
40. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
